HCPLive Network
  • AHA 2014
  • Family Practice Recertification
  • Internal Medicine World Report
  • Multiple Sclerosis Peer Exchange Video Series
  • Cardiology Review
  • Physician’s Money Digest
  • Surgical Rounds
Latest Specialty Headlines
Tuesday, November 25, 2014
By Rachel Lutz
Glucose intolerances may be linked to non-caloric artificial sweeteners, according to research published in Nature.
Tuesday, November 25, 2014
By Rachel Lutz
Research teams examining the safety and efficacy of zanamivir and oseltamivir for influenza treatment concluded they are not as effective as popularly believed.
Tuesday, November 25, 2014
By Rachel Lutz
HDL cholesterol may have atheroprotective qualities, according to a report from The New England Journal of Medicine.
Tuesday, November 25, 2014
By Amy Jacob
Study results published in the European Respiratory Journal show that rates of inflammatory bowel disease (IBD) incidence have significantly increased in individuals with asthma or chronic obstructive pulmonary disease (COPD).
Tuesday, November 25, 2014
By Amy Jacob
Regeneron Pharmaceuticals, Inc. and Sanofi recently announced the US food and Drug Administration (FDA) granted Breakthrough Therapy designation to dupilumab, a fully-human monoclonal antibody, to treat adults suffering from moderate to severe atopic dermatitis (AD)who had an insufficient response to or who were not suitable for topical prescription therapy.
Tuesday, November 25, 2014
Commoditycare is coming. To distinguish yourself, you will need to innovate and avoid the traps driving your competitors. Patients and payers will be watching you and voting with their wallets.
Tuesday, November 25, 2014
By Rachel Lutz
A drug to treat acquired hemophilia A was approved by the FDA, according to a statement made by manufacturer Baxter International Inc.
Tuesday, November 25, 2014
By Rachel Lutz
The FDA has approved Rixubis for the treatment of hemophilia B in children, manufacturer Baxter International Inc. announced.
Tuesday, November 25, 2014
By Rachel Lutz
Nonacog beta pegol was well-tolerated and effective for treatment of bleeding episodes in hemophilia B patients, and was associated with low annualized bleeding rates.
Tuesday, November 25, 2014
By Rachel Lutz
Inhibitor screening is important for all hemophilia patients, not just those at high risk, according to a study by the CDC.
Tuesday, November 25, 2014
By Rachel Lutz
Companies will use cell line development studies to determine where factor VIII manufacturing costs can be lowered without sacrificing efficacy.
Tuesday, November 25, 2014
By Rachel Lutz
During surgery, rFIXFc controlled hemophilia patients’ perioperative bleeding, according to a study published in the British Journal of Haemotology.
Email Signup
Breaking News
Onextron (clindamycin phosphate and benzoyl peroxide), 1.2%/3.75%, has been approved for the once-daily treatment of comedonal and inflammatory acne in patients 12 and older.
In the first test of an Ebola virus vaccine in the US, the University of Maryland announced it will soon start human trial.
Hysingla ER (hydrocodone bitartrate) is a single-entity oral hydrocodone tablet that is administered to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Physician's Money Digest
If investors want better outcomes, they would be better served if capital were allocated by diverse teams. And the issue is not just about white males. When a team or market is dominated by any ethnicity, it tends to make worse decisions.
If you’re able to predict the activity of Congress and the decision-making logic of the Supreme Court then you’re probably in good shape for developing a strategy to prepare for the Affordable Care Act. In the absence of such knowledge, you may at the least want to focus on the following:
Product News
Obizur (Antihemophilic Factor [Recombinant], Porcine Sequence) has been approved to treat acquired hemophilia A (acquired Factor VIII deficiency), a rare, non-inherited form of hemophilia.
The US Food and Drug Administration (FDA) approved Genzyme’s application to include new information about its multiple sclerosis drug teriflunomide (Aubagio) on its label. The new labeling content is efficacy and safety data from two Phase III trials of the drug.
The US Food and Drug Administration (FDA) has approved the use of an experimental drug to treat patients who have Ebola Virus Disease.
HCPLive Poll
Twitter Advice
Have you ever given medical or financial advice on Twitter?